Quantifying heterogeneity in SARS-CoV-2 transmission during the lockdown in India - Arinaminpathy, Nimalan; Das, Jishnu; McCormick, Tyler H.; Mukhopadhyay, Partha; Sircar, Neelanjan (medRxiv, 2020)
The novel SARS-CoV-2 virus shows marked heterogeneity in its transmission. Here, we used data collected from contact tracing during the lockdown in Punjab, a major state in India, to quantify this heterogeneity, and to examine implications for transmission dynamics. We found evidence of heterogeneity acting at multiple levels: in the number of potentially infectious contacts per index case, and in the per-contact risk of infection. Incorporating these findings in simple mathematical models of disease transmission reveals that these heterogeneities act in combination to strongly influence transmission dynamics. Standard approaches, such as representing heterogeneity through secondary case distributions, could be biased by neglecting these underlying interactions between heterogeneities. We discuss implications for policy, and for more efficient contact tracing in resource-constrained settings such as India. Our results highlight how contact tracing, an important public health measure, can also provide important insights into epidemic spread and control.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNA was supported by the UK Medical Research Council and by the Bill and Melinda Gates Foundation. PM is grateful for support from a Ford Foundation grant, which supports work on use of tacit knowledge in urban environments. TM was supported by the National Institute of Mental Health of the U.S. National Institutes of Health under award number DP2MH122405.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was reviewed by Georgetown University's IRB committee and granted an IRB exemption as "(4) Secondary research on data or specimens (no consent required)". The study ID for the IRB exemption is: STUDY00002690All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred to in the manuscript are available on request from the authors